Taimed Biologics Stock Fundamentals
| 4147 Stock | TWD 79.90 1.30 1.65% |
TaiMed Biologics fundamentals help investors to digest information that contributes to TaiMed Biologics' financial success or failures. It also enables traders to predict the movement of TaiMed Stock. The fundamental analysis module provides a way to measure TaiMed Biologics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to TaiMed Biologics stock.
TaiMed |
TaiMed Biologics Company Current Valuation Analysis
TaiMed Biologics' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current TaiMed Biologics Current Valuation | 17.73 B |
Most of TaiMed Biologics' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, TaiMed Biologics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, TaiMed Biologics has a Current Valuation of 17.73 B. This is 23.45% higher than that of the Biotechnology sector and 281.7% higher than that of the Health Care industry. The current valuation for all Taiwan stocks is 6.66% lower than that of the firm.
TaiMed Biologics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining TaiMed Biologics's current stock value. Our valuation model uses many indicators to compare TaiMed Biologics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across TaiMed Biologics competition to find correlations between indicators driving TaiMed Biologics's intrinsic value. More Info.TaiMed Biologics is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the TaiMed Biologics' earnings, one of the primary drivers of an investment's value.TaiMed Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses TaiMed Biologics' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of TaiMed Biologics could also be used in its relative valuation, which is a method of valuing TaiMed Biologics by comparing valuation metrics of similar companies.TaiMed Biologics is currently under evaluation in current valuation category among its peers.
TaiMed Fundamentals
| Return On Equity | -0.18 | |||
| Return On Asset | -0.062 | |||
| Profit Margin | (1.70) % | |||
| Operating Margin | (1.47) % | |||
| Current Valuation | 17.73 B | |||
| Shares Outstanding | 252.37 M | |||
| Shares Owned By Insiders | 17.27 % | |||
| Shares Owned By Institutions | 21.66 % | |||
| Price To Book | 6.45 X | |||
| Price To Sales | 55.99 X | |||
| Revenue | 413.44 M | |||
| Gross Profit | 177.82 M | |||
| EBITDA | (306.83 M) | |||
| Net Income | (470.93 M) | |||
| Cash And Equivalents | 1.02 B | |||
| Cash Per Share | 4.03 X | |||
| Total Debt | 536 M | |||
| Debt To Equity | 0.20 % | |||
| Current Ratio | 10.64 X | |||
| Book Value Per Share | 10.88 X | |||
| Cash Flow From Operations | (211.28 M) | |||
| Earnings Per Share | (2.36) X | |||
| Target Price | 88.0 | |||
| Number Of Employees | 37 | |||
| Beta | 0.51 | |||
| Market Capitalization | 17.62 B | |||
| Total Asset | 4.61 B | |||
| Z Score | 19.2 | |||
| Net Asset | 4.61 B |
About TaiMed Biologics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze TaiMed Biologics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of TaiMed Biologics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of TaiMed Biologics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.TaiMed Biologics Inc., a biotechnology company, develops health-care products. The company was founded in 2007 and is based in Taipei City, Taiwan. TAIMED BIOLOGICS operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange.
Pair Trading with TaiMed Biologics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if TaiMed Biologics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in TaiMed Biologics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to TaiMed Biologics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace TaiMed Biologics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back TaiMed Biologics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling TaiMed Biologics to buy it.
The correlation of TaiMed Biologics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as TaiMed Biologics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if TaiMed Biologics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for TaiMed Biologics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for TaiMed Stock Analysis
When running TaiMed Biologics' price analysis, check to measure TaiMed Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TaiMed Biologics is operating at the current time. Most of TaiMed Biologics' value examination focuses on studying past and present price action to predict the probability of TaiMed Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TaiMed Biologics' price. Additionally, you may evaluate how the addition of TaiMed Biologics to your portfolios can decrease your overall portfolio volatility.